The independent source for health policy research, polling, and news.
81-100 of 1,323 results
Xlear, a maker of xylitol gum, has sued the Federal Trade Commission, saying the onus should be on government to prove that ingredients don’t live up to advertised claims. RFK Jr.’s “medical freedom” allies have rallied to the cause.
Insurers will take drug costs, frequency of use, and other factors into account as they set premium amounts for the 2026 plan year.
The Health and Human Services secretary is winding down nearly $500 million in mRNA research funding, citing false claims that the technology is ineffective against respiratory illnesses — and notching a victory for critics of the covid vaccines. And President Donald Trump is demanding drugmakers drop their prices, quickly, but it’s unclear how he could make them comply. Lauren Weber of The Washington Post, Sandhya Raman of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join Թϲ’ Emmarie Huetteman to discuss these stories and more.
In their zeal to “Make America Healthy Again,” top Trump administration officials depict patients and the doctors who treat them as partly responsible for whatever ails them.
Medicaid may have monopolized Washington’s attention lately, but big changes are coming to the Affordable Care Act as well. Meanwhile, Americans are learning more about what’s in Trump’s big budget law, and polls suggest many don’t like what they see. Julie Appleby of Թϲ, Jessie Hellmann of CQ Roll Call, and Alice Miranda Ollstein of Politico join Թϲ’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews historian Jonathan Oberlander to mark Medicare’s 60th anniversary.
The Senate narrowly approved the Trump administration’s request to claw back about $9 billion for foreign aid and public broadcasting but refused to cut funding for the international AIDS/HIV program PEPFAR. Meanwhile, a federal appeals court ruled that West Virginia can ban the abortion pill mifepristone, which could allow states to block other FDA-approved drugs. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, Shefali Luthra of The 19th, and Sandhya Raman of CQ Roll Call join Թϲ’ Julie Rovner to discuss these stories and more.
Significant numbers of older people have the condition. Many find relief with an effective treatment that is being more widely prescribed.
In this second part of a two-part series on dealing with the high price of prescription drugs, experts share their insider tips.
Թϲ journalists made the rounds on national and regional media this week to discuss topical stories. Here’s a collection of their appearances.
Թϲ journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
The Supreme Court this week said Tennessee may continue to enforce its law banning most types of gender-affirming care for minors. The ruling is likely to greenlight similar laws in two dozen states. And the Senate is preparing to vote on a budget reconciliation bill that includes even deeper Medicaid cuts than the House version. Victoria Knight of Axios, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join Թϲ’ Julie Rovner to discuss these stories and more.
In Part 1 of a two-part series on dealing with the high price of prescription drugs, a father explains the strategies he used to get his daughter the medicine she needs to treat her epilepsy.
A new drug is helping families who’ve spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress — and a broader understanding of obesity — is now under threat as the government dismantles the pipeline for promising new research.
The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health budgets, and withdraws funding for bird flu vaccines, health security experts said.
Worried that President Donald Trump’s FDA might not act, a panel of cancer experts recommended that doctors consider testing before dosing patients with a commonly used but sometimes deadly cancer drug. It came too late for many patients.
Late last year, South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state programs covering these effective but expensive drugs. But access remains limited, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.
One thing experts agree on: The damage from the funding cuts will be varied and immense.
According to the timeline in the May 12 executive order, prescription drug price reductions would not happen "almost immediately,” but rather could take months or years. And extending the savings to Americans outside federal health insurance programs such as Medicare would likely require congressional action.
While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account for 90% of U.S. prescriptions — see trouble ahead for patients.
GOP-controlled House committees approved parts of President Donald Trump’s “one big, beautiful bill” this week, including more than $700 billion in cuts to health programs over the next decade — mostly from Medicaid, which covers people with low incomes or disabilities. Meanwhile, Health and Human Services Secretary Robert F. Kennedy Jr. testified before Congress for the first time since taking office and told lawmakers that Americans shouldn’t take medical advice from him. Julie Appleby of Թϲ, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine join Թϲ’ Julie Rovner to discuss these stories and more.
© 2026 KFF